It has long been known that most patients with bipolar disorder have a
course marked by multiple recurrence of major depressive and manic ep
isodes. More recently, many epidemiological studies have shown that at
least 50% of unipolar depressive patients have one or more subsequent
episodes of depression in their lifetimes. Likewise, relapse followin
g successful short-term treatment of depression is so common that it i
s now recommended to prolong treatment in the form of maintenance phar
macotherapy. Interest in preventing the recurrence of depression has b
een stimulated by the results from long-term trials involving antidepr
essant drugs and lithium. However, these pharmacological studies suffe
r somewhat from methodological deficits, making difficult any clear an
d complete interpretation of their results. While some methodological
recommendations have now been established to compensate for previous d
eficits (eg, definition of relapse and recurrence, duration of acute a
nd maintenance treatments, statistical analysis of efficacy), unfortun
ately, many key points still remain to be resolved (eg, selection of p
atients, dosage in maintenance and prophylactic phases, maximum length
of a course of treatment, etc).